Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by gericon Jun 27, 2013 4:09pm

42 Views

Post# 21577446

RE:BearDownAZ whats your 2 cents?

My interpretation is what you indicated in #1 scenario simply due to the wording....."unexpected strong placebo results". I think it amounts to human nature and just wanting to be a good patient. Did the placebo group a) stop smoking, b) start exercising, c) stop eating burgers and fries etc?
This is what they will be investigating.

The secondary endpoints are encouraging. Again they might be asking, was 26 weeks too short? Should they have opted for a full year study?

Bullboard Posts

Two micro-cap stocks with strong fundamentals